Transient receptor potential melastatin 2: a novel target for treatment of gout.
Open Access
- 4 September 2013
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 17 (11) , 1243-7
Abstract
Gout is an ancient autoinflammatory disease that affects millions of people worldwide. It is characterized by unbearable recurrent pain due to the massive local inflammation caused by the metabolic product, monosodium urate crystals. Although conventional therapies for gout can reduce the pain in patients, the severe undesirable side effects require the urgent need for novel therapies that can more specifically target gout-associated inflammatory pathways. Recent scientific advance on the mechanistic study of gout-associated inflammation is discussed and the potential of targeting the transient receptor potential melastatin 2 is highlighted as a novel therapeutic approach for the treatment of gout.Keywords
This publication has 30 references indexed in Scilit:
- New Therapies for GoutAnnual Review of Medicine, 2013
- Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during ApoptosisImmunity, 2012
- Uric acid, hyperuricemia and vascular diseasesFrontiers in Bioscience-Landmark, 2012
- Adenovirus Type 5 Rupture of Lysosomes Leads to Cathepsin B-Dependent Mitochondrial Stress and Production of Reactive Oxygen SpeciesJournal of Virology, 2011
- The inflammasome: an integrated viewImmunological Reviews, 2011
- Gout therapeutics: new drugs for an old diseaseThe Lancet, 2011
- A role for mitochondria in NLRP3 inflammasome activationNature, 2010
- Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilizationNature Immunology, 2008
- New Molecular Mechanisms on the Activation of TRPM2 Channels by Oxidative Stress and ADP-RiboseNeurochemical Research, 2007
- Gout-associated uric acid crystals activate the NALP3 inflammasomeNature, 2006